Japan Approves First Stem-Cell Treatments for Parkinson's and Heart Failure

Japan has granted conditional approval for two pioneering stem-cell treatments targeting Parkinson's disease and severe heart failure, potentially making them the world's first commercially available therapies using induced pluripotent stem (iPS) cells. Sumitomo Pharma received authorization for Amchepry, a Parkinson's treatment transplanting stem cells into the brain, while medical startup Cuorips gained approval for ReHeart, a heart muscle sheet therapy. The treatments could reach patients as early as this summer, with safety and efficacy supported by clinical trials. Health Minister Kenichiro Ueno expressed hope for global patient relief and pledged prompt distribution.